Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTROP-I vancomycin dosing optimization trial for Clostridioides difficile infection
2024-518607-21-00Phase 2Authorised
- Sponsor
- Bulovka University Hospital
- Start
- Sep 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vancomycin in Clostridioides difficile colitis (CDI) (2 arms), sponsored by Bulovka University Hospital. Primary endpoint: CDI recurrence within 60 days after end of study treatment. Planned start Sep 2025; status: authorised.
02
Drugs
vancomycin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2024-518607-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518607-21-00.